Wuxi AppTec Co (SHSE:603259) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603259 Wuxi AppTec Co Ltd SHSE:603259
97 GF Score
Price ¥123.69
GF Value ¥85.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Wuxi AppTec Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:603259
97GF Score
Wuxi AppTec Co Ltd SHSE:603259
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Wuxi AppTec Co (SHSE:603259) Overvalued in 2026?

Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued. The current stock price of ¥123.69 is trading 44.3% above its estimated GF Value™ of ¥85.70. GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.

Key valuation signals for SHSE:603259:

  • FFO:
  • GF Value™: ¥85.70 vs. price of ¥123.69 (44.3% above fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wuxi AppTec Co Business Description

Address 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
97GF Score

Get the complete analysis for SHSE:603259

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥123.69
Price
¥85.70
GF Value